← Eichor
Study identifier: NCT06029218 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy

Condition: Chordoma · Chondrosarcoma · Ewing Sarcoma  ·  Sponsor: Centre Antoine Lacassagne

PhaseNA
Planned participants106
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Thanks to the intrinsic qualities of the proton beam, proton therapy will reduce adverse effects of irradiation. The Proteus®One is the latest generation of proton therapy equipment, enabling the Centre Antoine Lacassagne to expand its range of treatments by carrying out new proton therapy treatments. It has an innovative compact isocentric rotating head (Gantry) that allows the radiation beam to be directed at different angles around the patient. In some cases, two beams are used to treat tumours, and by convention, both beams are delivered during the same session. However, it is necessary to position the patient before each beam, which is time-consuming because 2 beams have to be positioned very precisely each day. The aim of this study is therefore to assess the toxicity of proton therapy delivered by a single daily beam compared with proton therapy delivered by two daily beams, which is the conventional technique.

This description comes directly from the study's public registry record.

Talk to the study team

Clement DEVIC, PhD  ·  0492031511  ·  clement.devic@nice.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Centre Antoine lacassagneNice, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06029218